Hangzhou AGS MedTech Co. Ltd. A (688581) - Net Assets
Based on the latest financial reports, Hangzhou AGS MedTech Co. Ltd. A (688581) has net assets worth CN¥2.57 Billion CNY (≈ $376.22 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.70 Billion ≈ $394.83 Million USD) and total liabilities (CN¥127.24 Million ≈ $18.62 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 688581 current and non-current assets for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.57 Billion |
| % of Total Assets | 95.28% |
| Annual Growth Rate | 74.49% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 199.99 |
Hangzhou AGS MedTech Co. Ltd. A - Net Assets Trend (2021–2025)
This chart illustrates how Hangzhou AGS MedTech Co. Ltd. A's net assets have evolved over time, based on quarterly financial data. Check tangible equity quality of Hangzhou AGS MedTech Co. Ltd. A to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Hangzhou AGS MedTech Co. Ltd. A (2021–2025)
The table below shows the annual net assets of Hangzhou AGS MedTech Co. Ltd. A from 2021 to 2025. For live valuation and market cap data, see Hangzhou AGS MedTech Co. Ltd. A market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.52 Billion ≈ $368.21 Million |
+4.97% |
| 2024-12-31 | CN¥2.40 Billion ≈ $350.77 Million |
+8.55% |
| 2023-12-31 | CN¥2.21 Billion ≈ $323.13 Million |
+478.78% |
| 2022-12-31 | CN¥381.54 Million ≈ $55.83 Million |
+40.56% |
| 2021-12-31 | CN¥271.45 Million ≈ $39.72 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Hangzhou AGS MedTech Co. Ltd. A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 407.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥665.47 Million | 26.44% |
| Other Components | CN¥1.85 Billion | 73.56% |
| Total Equity | CN¥2.52 Billion | 100.00% |
Hangzhou AGS MedTech Co. Ltd. A Competitors by Market Cap
The table below lists competitors of Hangzhou AGS MedTech Co. Ltd. A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Alpargatas S.A
SA:ALPA3
|
$607.56 Million |
|
Granite Ridge Resources Inc
NYSE:GRNT
|
$607.69 Million |
|
NorthIsle Copper and Gold Inc
V:NCX
|
$607.94 Million |
|
J.S. Corrugating Machinery Co Ltd
SHE:000821
|
$607.94 Million |
|
Lotte Chilsung Beverage
KO:005300
|
$607.44 Million |
|
Franklin BSP Realty Trust Inc
NYSE:FBRT
|
$607.24 Million |
|
Interfor Corp
TO:IFP
|
$607.05 Million |
|
Beijing Navigation Control Technology Co. Ltd.
SHG:688282
|
$606.90 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hangzhou AGS MedTech Co. Ltd. A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,397,111,378 to 2,516,746,520, a change of 119,635,142 (5.0%).
- Net income of 221,712,129 contributed positively to equity growth.
- Dividend payments of 111,196,358 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥221.71 Million | +8.81% |
| Dividends Paid | CN¥111.20 Million | -4.42% |
| Other Changes | CN¥9.12 Million | +0.36% |
| Total Change | CN¥- | 4.99% |
Book Value vs Market Value Analysis
This analysis compares Hangzhou AGS MedTech Co. Ltd. A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.65x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | CN¥0.00 | CN¥51.18 | x |
| 2022-12-31 | CN¥6.28 | CN¥51.18 | x |
| 2023-12-31 | CN¥27.26 | CN¥51.18 | x |
| 2024-12-31 | CN¥29.60 | CN¥51.18 | x |
| 2025-12-31 | CN¥31.02 | CN¥51.18 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hangzhou AGS MedTech Co. Ltd. A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.81%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 37.34%
- • Asset Turnover: 0.22x
- • Equity Multiplier: 1.06x
- Recent ROE (8.81%) is below the historical average (13.78%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | 34.31% | 0.89x | 0.00x | CN¥104.80 Million |
| 2022 | 37.99% | 39.06% | 0.78x | 1.24x | CN¥106.81 Million |
| 2023 | 9.84% | 42.70% | 0.22x | 1.06x | CN¥-3.59 Million |
| 2024 | 12.24% | 46.09% | 0.25x | 1.06x | CN¥53.68 Million |
| 2025 | 8.81% | 37.34% | 0.22x | 1.06x | CN¥-29.96 Million |
Industry Comparison
This section compares Hangzhou AGS MedTech Co. Ltd. A's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $2,721,032,283
- Average return on equity (ROE) among peers: 13.84%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hangzhou AGS MedTech Co. Ltd. A (688581) | CN¥2.57 Billion | 0.00% | 0.05x | $607.54 Million |
| Shanghai Kehua Bio-Engineering Co Ltd (002022) | $3.11 Billion | -23.54% | 0.49x | $383.10 Million |
| Jiangsu Yuyue Medical Equipment & Supply Co Ltd (002223) | $1.11 Billion | 20.45% | 0.17x | $4.07 Billion |
| Double Medical Technology Inc (002901) | $441.78 Million | 42.71% | 0.27x | $2.73 Billion |
| Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) | $13.60 Million | 53.86% | 0.75x | $478.73 Million |
| Lepu Medical Tech Beijing (300003) | $16.74 Billion | 1.48% | 0.47x | $3.53 Billion |
| INKON Life Technology Co Ltd (300143) | $810.78 Million | 0.80% | 0.23x | $786.32 Million |
| Edan Instruments Inc (300206) | $1.73 Billion | 13.36% | 0.18x | $976.31 Million |
| Guangdong Biolight Meditech Co Ltd (300246) | $427.94 Million | 7.90% | 0.21x | $595.52 Million |
| Beijing Leadman Biochemistry Co Ltd (300289) | $1.44 Billion | 2.82% | 0.20x | $442.61 Million |
| Sinocare Inc (300298) | $1.39 Billion | 18.56% | 0.20x | $1.30 Billion |
About Hangzhou AGS MedTech Co. Ltd. A
Hangzhou AGS MedTech Co., Ltd., together with its subsidiaries, engages in the research, development, production, sale, and service of endoscopic minimally invasive diagnostic and therapeutic instruments in China and internationally. The company offers hemostasis products, including hemoclips and traction clips; biopsy products, such as disposable biopsy, swinging biopsy, and grasping forceps; an… Read more